The conflicting literature on HB-EGF, as a neuroprotective factor, and the neurotoxicity associated with the receptors EGFR/ErbB further stresses the need of novel model systems to investigate these pathways in more depths and their therapeutic potential for AD treatment. This evidence concerns the gene EGFR and Alzheimer disease.